BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is a debilitating and lethal disease. Despite significant advances in radiotherapy and surgical management, the 5-year survival rate for head and neck cancer has remained a dismal 50%. Advances in early detection have been made, but to improve patient outcomes better biomarkers and targeted therapeutic agents are needed. Novel biomarkers can improve early detection and provide data to optimize therapeutic strategy and patient survival, and could lead to potentially effective targeted therapies. OBJECTIVE: Report the advances in the discovery of novel biomarkers for HNSCC, and review the potential utility of biomarkers in the molecular diagnosis of HNSCC. METHODS: A review of the English literature (PubMed) from 1980 to 2009. RESULTS/ CONCLUSION: Currently the most widely accepted biomarker for HNSCC is high risk HPV status. EGFR is another promising biomarker, however, further research is necessary to determine its prognostic benefit. A large number of promising biomarker candidates are currently being evaluated including epigenetic, expression, and genomic based markers. Studies to validate the sensitivity and specificity of these biomarkers in clinical samples from adequately powered prospective cohorts are needed for successful translation of these findings into potential molecular diagnostic, prognostic, and therapeutic biomarkers for HNSCC.
BACKGROUND:Head and neck squamous cell carcinoma (HNSCC) is a debilitating and lethal disease. Despite significant advances in radiotherapy and surgical management, the 5-year survival rate for head and neck cancer has remained a dismal 50%. Advances in early detection have been made, but to improve patient outcomes better biomarkers and targeted therapeutic agents are needed. Novel biomarkers can improve early detection and provide data to optimize therapeutic strategy and patient survival, and could lead to potentially effective targeted therapies. OBJECTIVE: Report the advances in the discovery of novel biomarkers for HNSCC, and review the potential utility of biomarkers in the molecular diagnosis of HNSCC. METHODS: A review of the English literature (PubMed) from 1980 to 2009. RESULTS/ CONCLUSION: Currently the most widely accepted biomarker for HNSCC is high risk HPV status. EGFR is another promising biomarker, however, further research is necessary to determine its prognostic benefit. A large number of promising biomarker candidates are currently being evaluated including epigenetic, expression, and genomic based markers. Studies to validate the sensitivity and specificity of these biomarkers in clinical samples from adequately powered prospective cohorts are needed for successful translation of these findings into potential molecular diagnostic, prognostic, and therapeutic biomarkers for HNSCC.
Authors: K Zumbach; M Hoffmann; T Kahn; F Bosch; S Gottschlich; T Görögh; H Rudert; M Pawlita Journal: Int J Cancer Date: 2000-03-15 Impact factor: 7.396
Authors: Elin Ringström; Edward Peters; Masayuki Hasegawa; Marshall Posner; Mei Liu; Karl T Kelsey Journal: Clin Cancer Res Date: 2002-10 Impact factor: 12.531
Authors: Hsiao Wen Chang; Amy Chan; Dora Lai Wan Kwong; William Ignace Wei; Jonathan Shun Tong Sham; Anthony Po Wing Yuen Journal: Int J Cancer Date: 2003-07-20 Impact factor: 7.396
Authors: Ian M Smith; Chad A Glazer; Suhail K Mithani; Michael F Ochs; Wenyue Sun; Sheetal Bhan; Alexander Vostrov; Ziedulla Abdullaev; Victor Lobanenkov; Andrew Gray; Chunyan Liu; Steven S Chang; Kimberly L Ostrow; William H Westra; Shahnaz Begum; Mousumi Dhara; Joseph Califano Journal: PLoS One Date: 2009-03-23 Impact factor: 3.240
Authors: Wojciech K Mydlarz; Patrick T Hennessey; Hao Wang; Andre Lopez Carvalho; Joseph A Califano Journal: Head Neck Date: 2015-06-26 Impact factor: 3.147
Authors: Daniela Russo; Francesco Merolla; Silvia Varricchio; Giovanni Salzano; Giovanni Zarrilli; Massimo Mascolo; Viviana Strazzullo; Rosa Maria Di Crescenzo; Angela Celetti; Gennaro Ilardi Journal: Biomed Rep Date: 2018-07-27
Authors: Sahar A Saddoughi; Elizabeth Garrett-Mayer; Uzair Chaudhary; Paul E O'Brien; Larry B Afrin; Terry A Day; M Boyd Gillespie; Anand K Sharma; Christina S Wilhoit; Robin Bostick; Can E Senkal; Yusuf A Hannun; Jacek Bielawski; George R Simon; Keisuke Shirai; Besim Ogretmen Journal: Clin Cancer Res Date: 2011-07-26 Impact factor: 12.531
Authors: Wenyue Sun; David Zaboli; Hao Wang; Yan Liu; Demetri Arnaoutakis; Tanbir Khan; Zubair Khan; Wayne M Koch; Joseph A Califano Journal: Clin Cancer Res Date: 2012-01-06 Impact factor: 12.531
Authors: Maria J Worsham; Josena K Stephen; Kang Mei Chen; Meredith Mahan; Vanessa Schweitzer; Shaleta Havard; George Divine Journal: Clin Cancer Res Date: 2013-03-26 Impact factor: 12.531